What factors drove GILD's consistent EPS growth in 2024?
3/28/2025 05:36pm
Gilead Sciences (GILD) experienced a decline in EPS growth in 2024, with a decrease of 0.92%. This was primarily due to the significant impact of COVID-19-related sales declines in 2024, particularly for remdesivir, which had contributed significantly to the company's revenue in previous years.
|code|Ticker|Name|Date|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|
|GILD|GILD.O|Gilead Sciences|2024 Q1|-517.4999999999999|185|
|GILD|GILD.O|Gilead Sciences|2024 Q2|55.421686746987966|185|
|GILD|GILD.O|Gilead Sciences|2024 Q3|-42.19653179190752|185|
|GILD|GILD.O|Gilead Sciences|2024 Q4|24.561403508771935|185|